Leyden Labs reports positive Phase 1 results for RIG-101, an investigational intranasal therapy designed to strengthen antiviral defenses and help prevent virus-triggered asthma exacerbations. The results support RIG-101’s advancement into Phase 2 clinical development. The post Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients appeared first on Leyden Labs .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules